AAPL 242.195 -3.2845% MSFT 415.4 -1.4472% NVDA 136.11 1.3553% GOOGL 188.45 -0.449% GOOG 189.67 -0.4043% AMZN 218.77 -0.2826% META 592.1525 1.1345% AVGO 230.54 -0.5607% TSLA 377.02 -6.6412% TSM 199.64 1.0887% LLY 774.59 0.3355% V 312.71 -1.0537% JPM 239.57 -0.0584% UNH 504.27 -0.3143% NVO 87.56 1.7903% WMT 89.7 -0.7194% LVMUY 128.99 -1.3008% XOM 107.02 -0.5113% LVMHF 645.0 -1.7816% MA 518.315 -1.5677%
Last update at 2024-06-04T03:31:53.321270Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -58.79500M | -19.76900M | -76.10000M | -32.55700M | -73.66700M |
| Minority interest | - | - | - | - | - |
| Net income | -58.79500M | -19.76900M | -76.10000M | -18.00300M | -73.66700M |
| Selling general administrative | 14.71M | 45.31M | 43.34M | 27.01M | 29.45M |
| Selling and marketing expenses | 9.41M | - | - | - | - |
| Gross profit | -5.74000M | -1.36500M | -1.23900M | - | - |
| Reconciled depreciation | 2.16M | 2.82M | 2.55M | 0.48M | 0.40M |
| Ebit | -56.81300M | -19.00600M | -74.78600M | -32.51900M | -56.53700M |
| Ebitda | -12.67600M | -48.26000M | -53.20800M | -61.14700M | -56.14100M |
| Depreciation and amortization | 44.14M | -29.25400M | 21.58M | -28.62800M | 0.40M |
| Non operating income net other | - | - | 0.04M | - | - |
| Operating income | -56.81300M | -19.00600M | -74.78600M | -32.51900M | -73.53500M |
| Other operating expenses | 37.01M | 53.46M | 56.30M | 47.07M | 65.04M |
| Interest expense | 21.07M | 2.30M | 1.36M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | - | -2.30300M | -1.35900M | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 23.05M | 3.84M | 1.40M | -14.55400M | -0.13200M |
| Total revenue | 1.27M | 1.08M | 0.49M | 0.00000M | 0.00000M |
| Total operating expenses | 30.00M | 51.01M | 54.57M | 47.07M | 65.04M |
| Cost of revenue | 7.01M | 2.44M | 1.73M | - | - |
| Total other income expense net | -1.98200M | -0.76300M | -1.31400M | -0.03800M | -8.63100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -58.79500M | -19.76900M | -76.10000M | -32.55700M | -73.66700M |
| Net income applicable to common shares | -58.79500M | -17.34700M | -76.10000M | -32.55700M | -73.66700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 10.03M | 53.28M | 68.73M | 54.21M | 35.02M |
| Intangible assets | - | 21.68M | 24.25M | 26.40M | 26.40M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.75M | 2.06M | 3.35M | 2.40M | 2.51M |
| Total liab | 34.27M | 40.05M | 83.53M | 70.93M | 103.37M |
| Total stockholder equity | -24.24200M | 13.23M | -14.79900M | -16.72100M | -68.34700M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 11.93M | 11.96M | 13.46M | 7.12M | 20.13M |
| Common stock | 0.02M | 0.98M | 0.49M | 0.09M | -68.34700M |
| Capital stock | 0.02M | 0.98M | 0.49M | 0.09M | - |
| Retained earnings | -190.90400M | -132.08900M | -112.32000M | -36.22000M | - |
| Other liab | 10.70M | 18.10M | 56.64M | 62.77M | 80.59M |
| Good will | 2.13M | 2.13M | 2.13M | 2.13M | 2.13M |
| Other assets | 0.85M | 0.96M | 0.58M | - | - |
| Cash | 5.26M | 15.89M | 30.34M | 17.74M | - |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 21.46M | 15.65M | 18.13M | 7.71M | 22.78M |
| Current deferred revenue | - | 5.54M | 4.35M | 2.93M | - |
| Net debt | 1.86M | -7.36000M | -20.56400M | -16.96700M | - |
| Short term debt | 5.60M | 2.22M | 1.02M | 0.32M | - |
| Short long term debt | 5.60M | 2.22M | 0.68M | - | - |
| Short long term debt total | 7.12M | 8.53M | 9.78M | 0.77M | - |
| Other stockholder equity | 166.65M | 144.33M | 98.28M | 20.25M | -67.87500M |
| Property plant equipment | 0.70M | 5.01M | 5.05M | 5.55M | 3.98M |
| Total current assets | 6.35M | 23.49M | 36.72M | 20.14M | 2.51M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -26.36900M | -10.57900M | -41.18000M | -45.24800M | -96.87400M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.34M | 0.54M | 0.05M | - | - |
| Long term debt | 1.52M | 6.31M | 8.47M | - | - |
| Inventory | 0.00000M | 5.00M | 2.98M | - | - |
| Accounts payable | 3.93M | 1.47M | 3.65M | 0.27M | 2.65M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -1.24800M | -0.84000M | -0.47200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.49M | 0.09M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -112.32000M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.85M | 0.96M | 0.58M | 34.08M | 32.51M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3.69M | 29.78M | 32.02M | 34.08M | 32.51M |
| Capital lease obligations | - | - | 0.63M | 0.77M | - |
| Long term debt total | - | - | 8.47M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.02000M | 0.00900M | -0.63900M | -1.48400M | -3.45200M |
| Change to liabilities | -1.30000M | -1.48600M | 4.61M | -8.99300M | 0.49M |
| Total cashflows from investing activities | -0.02000M | -0.19400M | -0.63900M | -1.48400M | -3.45200M |
| Net borrowings | -2.24400M | -2.24400M | 10.04M | 10.04M | 10.04M |
| Total cash from financing activities | 17.18M | 35.01M | 57.30M | 69.27M | 63.20M |
| Change to operating activities | 1.44M | 0.92M | -0.95100M | 0.12M | -0.04600M |
| Net income | -58.79500M | -19.76900M | -76.10000M | -32.55700M | -73.66700M |
| Change in cash | -10.63200M | -14.45100M | 12.60M | 17.74M | 17.74M |
| Begin period cash flow | 15.89M | 30.34M | 17.74M | 0.00000M | 0.00000M |
| End period cash flow | 5.26M | 15.89M | 30.34M | 17.74M | 0.00000M |
| Total cash from operating activities | -27.79300M | -49.27000M | -44.05800M | -50.04400M | -59.75100M |
| Issuance of capital stock | 20.40M | 30.82M | 45.01M | - | - |
| Depreciation | 2.16M | 2.82M | 2.55M | 0.48M | 0.40M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.28000M | -2.02400M | -2.97800M | -2.97800M | -2.97800M |
| Change to account receivables | 0.21M | -0.49100M | -0.05100M | -0.05100M | -0.05100M |
| Sale purchase of stock | - | - | 25.76M | - | - |
| Other cashflows from financing activities | -0.97400M | 4.19M | 12.29M | 69.27M | 63.20M |
| Change to netincome | 28.78M | -29.23700M | 28.86M | -9.09100M | 13.07M |
| Capital expenditures | 0.02M | 0.20M | 0.64M | 1.48M | 3.45M |
| Change receivables | - | - | -0.05100M | - | - |
| Cash flows other operating | - | - | -0.95100M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 12.60M | - | - |
| Change in working capital | 0.06M | -3.08000M | 0.63M | -8.87600M | 0.45M |
| Stock based compensation | 1.40M | 4.79M | 9.34M | 5.46M | 4.57M |
| Other non cash items | 27.38M | -32.41500M | 2.78M | -14.55400M | 8.50M |
| Free cash flow | -27.81300M | -49.47300M | -44.69700M | -51.52800M | -63.20300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BXRX Baudax Bio Inc |
- -% | - | - | - | 0.75 | 0.68 | 6.63 | -0.2569 |
| NVO Novo Nordisk A/S |
1.54 1.79% | 87.56 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.10 1.28% | 87.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.28 0.07% | 402.98 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-0.075 0.01% | 712.25 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
490 Lapp Road, Malvern, PA, United States, 19355
| Name | Title | Year Born |
|---|---|---|
| Dr. Geraldine A. Henwood Ph.D. | Pres, CEO & Director | 1952 |
| Ms. Jillian Dilmore | Corp. Controller, Corp. Sec., Interim Principal Financial & Accounting Officer | NA |
| Ms. Diane Myers | Sr. VP of Regulatory & Quality | 1964 |
| Dr. Geraldine A. Henwood Ph.D. | President, CEO & Director | 1952 |
| Mike Choi | Vice President of Financial Planning & Analysis | NA |
| Ms. Natalie McAndrew | Consultant & Principle Accounting Officer | 1971 |
| Dr. Chan Kim Yong Ph.D. | Chief Scientific Officer & Director | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...